<SEC-DOCUMENT>0001193125-21-329003.txt : 20211115
<SEC-HEADER>0001193125-21-329003.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115081203
ACCESSION NUMBER:		0001193125-21-329003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211115
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				364108129
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40551
		FILM NUMBER:		211406512

	BUSINESS ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		925-368-8508

	MAIL ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d255444d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abos="http://www.acumenpharm.com/20211115" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-11-15_to_2021-11-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-11-15_to_2021-11-15">0001576885</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="abos-20211115.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-11-15_to_2021-11-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001576885</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-15</xbrli:startDate> <xbrli:endDate>2021-11-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-11-15_to_2021-11-15">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt:datemonthdayyearen">November 15, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-11-15_to_2021-11-15">Acumen Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-11-15_to_2021-11-15">001-40551</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-11-15_to_2021-11-15">36-4108129</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-11-15_to_2021-11-15">427 Park St.</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-11-15_to_2021-11-15">Charlottesville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-11-15_to_2021-11-15">22902</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-11-15_to_2021-11-15">(434)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-11-15_to_2021-11-15">297-1000</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-11-15_to_2021-11-15">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-11-15_to_2021-11-15">ABOS</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2021-11-15_to_2021-11-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;15, 2021, Acumen Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) reported financial results and business highlights for the quarter ended September&#160;30, 2021. A copy of this press release (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Earnings Press Release</span></span>&#8221;) is furnished as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;and</span> is incorporated by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (including Exhibit&#160;99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160; Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">Exhibit<br />No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d255444dex991.htm">Earnings Press Release, dated November&#160;15, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Acumen Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dated: November&#160;15, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Zuga</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Matthew Zuga</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer and Chief Business Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d255444dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g255444g82g25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acumen&#146;s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered
and developed to selectively target toxic amyloid-beta oligomers (A&szlig;Os) to enter clinical trials </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Enrolled first patients in <FONT STYLE="white-space:nowrap">INTERCEPT-AD,</FONT> a multi-center, randomized,
double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer&#146;s disease </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Closed initial public offering in July 2021, with aggregate net proceeds of $168.6</B><B></B><B>&nbsp;million
</B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charlottesville, Va, and Carmel, In., November</B><B></B><B>&nbsp;15, 2021</B> &#150; <U>Acumen Pharmaceuticals, Inc.</U>
(NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer&#146;s disease (AD), today reported financial results for the quarter ended September&nbsp;30, 2021 and provided
recent business highlights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Starting with our successful IPO in early July, the third quarter of 2021 marked the beginning of the next phase of
life for our company. In October 2021, we announced the screening and initial dosing of our first patient in <FONT STYLE="white-space:nowrap">INTERCEPT-AD,&#148;</FONT> said Daniel O&#146;Connell, President and Chief Executive Officer at Acumen. <FONT
STYLE="white-space:nowrap">&#147;INTERCEPT-AD</FONT> is investigating the safety, tolerability, pharmacokinetics and target engagement of our product candidate ACU193 in a Phase 1 clinical trial involving early Alzheimer&#146;s patients. ACU193 is
differentiated as the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (A&szlig;Os) to enter a clinical trial. We have cleared our sentinel safety review and are continuing to recruit
patients in <FONT STYLE="white-space:nowrap">INTERCEPT-AD.</FONT> We believe we have the resources to execute against our current strategic plan with our existing cash and cash equivalents and marketable securities, which we believe will be
sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through 2024.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Business Highlights
and Anticipated Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ACU193 Clinical Development </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> is recruiting; sentinel safety review complete and Cohort
1 is enrolling.</B>&nbsp;Patient screening and enrollment is ongoing for <FONT STYLE="white-space:nowrap">INTERCEPT-AD.</FONT> Although Acumen has experienced delays in clinical site activation and patient enrollment in <FONT
STYLE="white-space:nowrap">INTERCEPT-AD,</FONT> which Acumen believes is a result of the rise of the Delta variant of <FONT STYLE="white-space:nowrap">COVID-19</FONT> early in the third quarter of 2021, Acumen continues to anticipate topline data
from this trial by the end of 2022, subject to the rate of site activation and patient recruitment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g255444g1113045949789.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate </I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Closing of Initial Public Offering. </B>In July 2021, Acumen issued an aggregate of 11,499,998 shares of
common stock, including shares pursuant to the underwriters&#146; exercise of their full over-allotment option, in an initial public offering, resulting in aggregate net proceeds of $168.6&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Third Quarter 2021 Financial Results </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Balance.</B> As of September&nbsp;30, 2021, our cash and cash equivalents totaled $135.8&nbsp;million and
our marketable securities totaled $94.1&nbsp;million, compared to cash and cash equivalents of $43.8&nbsp;million and no marketable securities as of December&nbsp;31, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development (R&amp;D) Expenses. </B>R&amp;D expenses were $1.8&nbsp;million and $6.6&nbsp;million
for the three- and nine-month periods ended September&nbsp;30, 2021, respectively, compared to $3.0&nbsp;million and $7.0&nbsp;million for the three- and nine-month periods ended September&nbsp;30, 2020, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative (G&amp;A) Expenses.</B> G&amp;A expenses were $2.1&nbsp;million and
$4.5&nbsp;million for the three- and nine-month periods ended September&nbsp;30, 2021, respectively, compared to $0.2&nbsp;million and $0.7&nbsp;million for the three- and nine-month periods ended September&nbsp;30, 2020, respectively.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Loss from Operations.</B> Losses from Operations were $3.9&nbsp;million and $11.2&nbsp;million for the three-
and nine-month periods ended September&nbsp;30, 2021, respectively, compared to $2.5&nbsp;million and $6.6&nbsp;million for the three- and nine-month periods ended September&nbsp;30, 2020, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net Loss.</B> Net Losses were $3.9&nbsp;million and $92.3&nbsp;million for the three- and nine-month periods
ended September&nbsp;30, 2021, respectively, compared to $2.5&nbsp;million and $6.6&nbsp;million for the three- and nine-month periods ended September&nbsp;30, 2020, respectively. Net losses in 2021 include a
<FONT STYLE="white-space:nowrap">non-cash</FONT> expense that represents the changes in fair value of Acumen&#146;s Series B tranche liability and Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant liability. The tranche liability and
warrant liability were initially recorded at fair value as a liability on Acumen&#146;s balance sheet and were subsequently <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value at the end of each reporting period. The increases in the
fair value of these instruments were recognized as a component of other expense. The second tranche of the Series B Preferred Stock financing round closed in June 2021 and, as a result, the remaining value of the tranche liability was reclassified
to convertible preferred stock on Acumen&#146;s condensed balance sheet. Additionally, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant was exercised in June 2021, and the remaining value of the warrant liability was reclassified to
convertible preferred stock on Acumen&#146;s condensed balance sheet. Upon the closing of the initial public offering, all outstanding share of convertible preferred stock converted into equivalent shares of common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g255444g1113045949789.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ACU193 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACU193 is a monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble A&szlig;Os, which Acumen believes are the most toxic and
pathogenic form of A&szlig;, relative to A&szlig; monomers and amyloid plaques. Soluble A&szlig;Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting
toxic soluble A&szlig;Os, ACU193 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in AD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 62 individuals with early AD (mild cognitive impairment or mild dementia due to AD) are expected to be randomized into this double-blind,
placebo-controlled, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study of ACU193. <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> is designed to establish safety and proof of mechanism. It
consists of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193. The study is enrolling at multiple
investigative sites located in the United States. More information can be found on www.clinicaltrials.gov, NCT identifier NCT04931459. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Acumen
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acumen Pharmaceuticals, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN., is a clinical stage
biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer&#146;s disease. Acumen&#146;s scientific founders pioneered research on toxic soluble A&szlig;Os, which a growing body of evidence indicates are primary
triggers of Alzheimer&#146;s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A&szlig;Os in a Phase 1 clinical trial
involving early Alzheimer&#146;s disease patients. For more information, visit <U>www.acumenpharm.com.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.&nbsp;Any statement
describing Acumen&#146;s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an <FONT STYLE="white-space:nowrap">at-risk</FONT> statement.&nbsp;Words such as
&#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;would,&#148; &#147;seeks,&#148; &#147;aims,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;will&#148; and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen&#146;s business, Acumen&#146;s ability to achieve its strategic and
financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen&#146;s product candidate, ACU193, including its potential for
improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the <FONT STYLE="white-space:nowrap">INTERCEPT-AD</FONT> trial, including the expected timing of reporting data, and risks
and uncertainties relating to the progression and duration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and responsive measures thereto and related effects on Acumen. These statements are based upon the current beliefs and
expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g255444g1113045949789.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amplified by the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. These and other risks concerning Acumen&#146;s programs are described in additional detail in
Acumen&#146;s filings with the Securities and Exchange Commission (&#147;SEC&#148;), including in Acumen&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2021, and future filings and
reports by Acumen, including Acumen&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2021. Copies of these and other documents are available from Acumen.&nbsp;Additional
information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any
forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@acumenpharm.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>abos-20211115.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/15/2021 6:06:55 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:abos="http://www.acumenpharm.com/20211115"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acumenpharm.com/20211115"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20211115_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20211115_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>abos-20211115_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/15/2021 6:06:55 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>abos-20211115_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/15/2021 6:06:55 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abos-20211115.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g255444g1113045949789.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g255444g1113045949789.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O .@# 2(  A$! Q$!_\0
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?[(K,A)1B,E<C!QZ<5,*KBFNC'*"DT^P^BBBLBS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g255444g82g25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g255444g82g25.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M>FY2P\X1G2E+=JUI)M65XS4OER]SARC'_7\(JLK*K"3C-132T=XM)ZV<6O\
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MJ> PJPU&/NJ,I)>ZEI&*^&"72V[\_0^9Q5?VU2R?N0O;S?5_HO(\H90R,AR
MRE>." 1C(/8UVK2WD<I^ZWPV_:5UWQC\$OA\-+'V/6T\-VFB^)M;8A[@ZMHB
M_P!DWGV!"S>3)-]E2X:>3Y@;GY$3 :OY<\0\[Q639YF.28&F\-R2C4]O*W-[
M.O%58>Q6T4E)Q]H];Q?*DU<]I8^I*A3A#W9**4I=;K33M?>_W'D_BKQ8-+,L
M,,IN]9N"TDKRN9C;M)R;FZ=R3+<,3D*Q))^9N.OX9F>9_5N:$)>TQ<]6V[\E
M_M3;NW)[I/7J]-_'Q6+5&\8/FK/Y\OF^[[+YL\8EEDFD>661Y)9'+R2.2SN[
M')9F/4U\C*4IR<I-RE)W;>[?F>(VVVV[M[M[GW#^Q]X"W/K?Q&OH>$\SP[X>
M+J.H*2:S?1YY'(M[16']VY7/6OV3PJR37%Y]6AI&^%PMUZ.O47_DM)/RJ(^F
MX>PFM3&26W[NG_[?+\HK_MX^TO$_B31_!WAS7O%?B&\2PT+PUI&H:YJ][(0%
MM=.TNUEO+N7!(W,L$+[5!RS84<D5^VT*-3$5J6'HQYJM:<80CWE)I)?>_D?3
M5:D*%.=6H^6%*+E)]E%7?Y'\BGQ=^).O_&_XK>+_ (BZG#<3:KXV\0O-IFEH
M6FFL]/9X].\->'[5>2QMM-CL+15'WG5FZN<_O>7X.EEF P^$@U&GAJ=I2V3E
M\52;[<TN:3['Y1B\14QN+JUG\566BWLMHI6O?EBDE;=)%3XH?#?Q;\%?B'K?
MP_\ %.+#Q5X4N-,FDN+"1Q&DEW86.M:;?Z?<85F58[J!DD7I)$V#\M5@L9A\
MQPE/%4/>H5U))22Z2<)*2UZIZ=A8C#U<#B)4*ONU*35[-]4FK/3HUMW/Z@OV
M3/C9#\?/@5X,\=RS1MXACM#X>\9P(0#;>+=#6.TU5F0?ZM+P?9]1B7M#J47I
M7XKGN6O*LSQ&%2M1OST7WI3UCZ\NL'YQ9^EY7C%C<%1K7O.*Y:G^..C=NG,K
M22Z*5CZ1KQST#"\3^)=#\&>'=;\6>)M1M](\/^'-+O=9UG4KIMD%GI^GP/<W
M,SXY8B.,[44%G8JB LP!UH4:N(K4J%&#G5JR4(16[DW9+R]=EN]"*E2%&G.K
M4ERTZ:<I-]$E=_\ #=>A_,'^U?\ M?\ CK]I?Q)>6K75YH'PHT[4';PIX&AD
M:*.YB@<QVFM^*5B8_P!JZ],O[Q87+PV?G>5;J7$DT_[3D7#^%R6C%\JJXZ4?
MWM9]+[PIW^&"VOHY6O+2R7YMFF;U\?5E%-T\-%^Y!/MM*5MY>>RVCI=OUWX'
M?\$S_C7\5-)L/$WC+4-.^$GAO48H;FQM]<L;C5/&%W9RC='<_P#"-PS6R:4C
M1_,J:A>03X92;<*V:\_,N,LMP-25##PECZU-M-P:C2373VC3YK/^2+C_ 'CJ
MP7#>+Q,(U*LEA:<DFE)-SM_@5K:?S2B_)H^E-2_X(_P"V)T?X]737JI\J:I\
M/K<6CR#NS6?BD21I[ .?>O'AQ^[_ +S*UR_W:[O^-*WY'HRX227N8VS7>EI_
MZ<=ON/._AI_P3_\ CQ\#?VCO@OXLN[30_'7@?1OB%I%WJ7B;PI=.)='LT2Y'
MVW6-"U1(;NT@5F7?-;&]CC)&^0 @GJQG%669EE&84(N>%Q,Z$U&G56DGVA.-
MXM]D^5OL987(L9@<?AZKM5HQJ1O*#>B4HOWHM)JUKO1Q5M[V/UL_:LX_9I^.
MO;'PL\9^W31+NOA,BTSG*_+$T?\ TM'T^:?\BW'>5&I_Z2S^<C]B4?\ &5OP
M(]O&1_30-9K]=XDTR+,_^O7_ +?$_/\ (_\ D9X7_$?U;U^&GZ>% '\CO[5W
M_)R7[0?M\5_'GX8UF[%?O.1:9-E7EA:/_I"/RO,O^1GC/^O]3_TXS^H_X%\?
M!+X.^WPL^'OZ>$M(K\4S/3,LP\L37_\ 3LS]*P.F"P?E0I?^FXG\XLWQ[\:_
MLZ?M?_&'Q_X.G:6)?BW\0;/Q/X;GF>/2_%GA\^,-4>YTJ_50PCG7YI;2[",]
MM.%=0R-)'+^O+*L-FW#^7X7$1L_JM!TZB7O4I^RC:4?+I*.THZ:.S7YZL?6R
M_-L75I/3ZQ54X/X91]H[I]O)I73L];6/Z=]%UBUUK3K*^MRB/=:?IU_+9F:*
M2XLAJ-G%>P0W*QL=C^5*,$@!@,KD&OQ>I3E2G*#VC*44[63Y6XMKYKY'Z3":
MG&+6ETFU?575TF:U9EF%XG\3>'_!?A[6/%?BK5K+0O#OA^PN-3UC5]0E$%G8
M6-JA>6:5SDDX 58T#/([+'&K.ZJ=:%&KB*M.A0INI6JR480BM6WLO\WLEJ[)
M$5*D*-.52I)0IP5Y-[)+^M%NWHM3^8?]LW]K77OVF_%TT=@;W1_A5X7ENU\%
M>&YB8I;Z01R0/XL\00(Q5]9NHBPA@)9;&WD\E"99+B2;]GX>R&EDN'O*T\=6
M2]K473K[*#_DB]W]N2N]%%+\YS;-9YAB(QA>.&I2]R/?6W-*VCD_N2T75R_I
MJ\!C'@?P8/3PIX='Y:19U^-8K3$XCRJU/_2V?HE#2A1\H0_])1_(S\:6V?%_
MXNOC.WXF>/FQTSM\4ZJ<9K][RW_D7X#_ +!Z'_IJ)^48M?[9BEM^^J_^EL_4
M'0_^"2>I:SHNCZPOQTM+==5TO3]36 ^ I)/(%]:0W0A\S_A)U\S9YNW=M7.W
M.!G%?%5./(4JE2E_9C?LY2C?V]OA;5[>STV/I8<*2G"$_KJCS13M[+:ZO_.:
MG_#H#5/^B\VG_AOY/_FJJ/\ 7^G_ -"M_P#@_P#^Y%_ZI3_Z#E_X*_\ MS[]
M_8]_9:N/V5_"GC#PU<>-(O&C>*?$MOX@6\BT-M#%DMOI-KIGV4PMJ5YYY)MO
M,\P.F-^W;QD_*<09VL[KT*T<,\-["FX<KGSW]YRO?EC;>UM3W\IRUY91J4G5
M57FDG=1Y=O*[/S;_ ."MEU=6/Q;^"M[8W5S8WUAX*UF\LKVSGDMKRRO+;Q-:
MS6UW:7,++);W,,T:2)(C*RL@(((K[#@.,98',82BI1E5BG%JZ:=.S33T::T:
M9\]Q2W"OA)1;C*,;IK1IJ4K-6['U?^PG^W%:_&JPLOA7\4K^VLOBYI=ILTG5
MI3';6OQ&TZTBR]U HVQP^*H(4+W=F@ N%5KNW7:)HK;P^)N&I9;*6.P,7+ 2
M?O16KP\F]GU=)O2,OLOW9=&_3R/.EC(QPV)?+BH+W9=*J7_MZ6ZZ[KJE^FE?
M&'T9\:?\%!./V0?C)_V#?#@_\O/PX*^BX4TS_+_*53_TS4/(SW3*L5Y*'_IR
M!^-'_!-+_D[GP;[>%/'OX?\ $A<5^A<9:9#7_P"OE'_TXCY'AO3,J?I/_P!-
MS/Z8J_&S]%"@ H * "@#,UG6-/T#3+S5]4N%M;"QA,T\K<G PJ1QH.9)G<JB
M(.69@!UK?#8:MBZ]/#8>'/5J.T5^;;Z**U;V239SXO%4,%AZN*Q,U2HT(\TF
M_N22ZR;LHI:MM)'YZ_$SQW?^+;G5M=O"UM:66GWPTFQ+%H]/M(X9&CW '#W,
MC*CS..K84?(B@?K^2951RZGA\)27-4J3A[6=K.I-M)^D8JZ@NBUW;/P_/,XK
MYKB:N+J_NZ5*,E1IWNJ4%=KUG*R<WU>B]V*/G;X,?&;7_@_?:Y+ID$-]:>(-
M*-I+8W4KI:6^KP@_V3K)10?,-LTDR21C;YL4Q7<I167ZCB[AZEGN!IM7CBL!
M)U*;BO>G3_Y>T;].=)2B^DXK3WF<'!>?O(\S5.K*V!Q_+2K7>E.=[4JUO[C;
MC/\ N2;^RCY[^.'Q'U/9>Q7.ISW_ (K\6--<ZIJ,LFZYAL)28YYR1CR7G"FV
M@1=JQQ))L 5$KXS+<)!<O+!0H4+*,4M+K9?+>7=VONS]GQE=P7LT_?GN^T?^
M#LO(^1    . . .F .E>Z>3MY6#_ "/Z4;>5@/JW]FOXH)9:5XP\"VK^;?V5
MW;:Y8RDJT%K%>I]AU-(P2?-FCN(+-L#Y5:X.<D$'^9?I!X*ME[R+B'#TN7Z_
M&IE]2I;2,Z*=>A-KO*G.K&%]_9WV2ORRS",/:4:/O3CM+[*Z2LNK6GE?T/9G
M=Y'>21V>1V+N[DL[NQRS,QY+$]Z_E1MR;E)N4F[MO5WZMLX&VVVW=O=O<O:3
MI=]KFJ:;HNF1&?4=7OK73;&(#.^YNYD@BSCHBL^YCV56)X%;87#5L9B</@\-
M'GKXJI"E3C_?G)1C\E>[[)-E4X2JSA2IJ\ZDE&*\V[(_9WP7X6L?!/A70O"N
MG ?9M%T^"T\S&TW$ZC?=W;C_ )Z3W;S3-[RFOZVRC+:.3Y;@LLP_\/!THPO_
M #26LYOSG-RF_-GZ-AJ$<+0I8>'PTHI>KZOYN[^9^8?_  52^.7_  BWP\T#
MX(:)>>7K7Q'E76?%"POMEMO!.B7:-#:R@<JNJZ[%#&,'YH=(O$(*OS^E\#Y9
M[?%U<RJ1_=X-<E.^SK36K7^"#^^<7T/GN)L=['#PP=-VG7]Z=MU"+TV::YI*
MZ?\ <:>C/SX_X)V_!H?%C]HO0]5U&T^T>%_A7 GCO6/,0-;S:O;3BW\(Z>^Y
M2K.^LG[=Y9'S1Z+,.E?6<6YC]0RBI3A+EK8U^QAW46KU9>BA[ODYH^?X>P?U
MK'PG)7IX;]X^UT_<7D^:SVU49'UC_P %9O@V8+WP%\=M)M,172#X>^,9(DP!
M/']IU/PEJ$Y7J63^V+%I& QY=DF>0*\+@3,/=Q663E\/[^DGVTC5BO1\DDO.
M3/5XIP=G0QL%_P!.Y[[J[@[+NN9-OI&*/'?^"7GQQ_X0+XO:E\)M9O!#X;^+
M$"'2!,X6&S\=Z)!++IX0MPAU321=V9 P9)[33TY(%>AQKEGUK 0QU*/[[ /W
MK;NC-I2_\ E:7E%S9R<,XWV&*EA)NU/$+W>RJ+5>2YE>+ZN3BNA_0W7Y,??'
MY7?\%7OB/?>&O@SX.^'FG3O!_P +)\62-K/ER%6GT#PA;PZI-9.JD9AFUF[T
M1V!X(M2IX8U]OP+@XULQKXJ:O]3I+D\IU6XI^J@IKYGS/%&(E1P=*A%\OMYN
M_G&G9V_\"E%_]NGQ;_P3'^ .C_%#XHZY\2?%>GPZEX=^$R:7+I&GW4:R6=[X
MXU9KB72KFXA?*SQZ396<]XL; J+FXL9#GRL'Z/C/-:F"P5+!X>;A6QW,IR6C
M5&%E))].=M1O_*I+J>-PU@(8C$3Q%6/-3PW*XIK1S=^5^?+RM[;\OFC^B.OR
M4^_"@ H ^?OVKN/V:/CM[?"WQE_Z9;NO6R+_ )'.5]/]IH_^EH\_-=,MQWE1
MJ?\ I+/YR_V)!_QE=\"/;QB_Z>']:K]<XETR+,_*E_[?$^ R/3,\+_B/ZM:_
M#3]/"@#^1O\ :L_Y.0_:#]OBQX]_36KP5^]9'ID^5?\ 8+0_](1^5YEIF>+\
MJ]3_ -.2/ZD?@9Q\$_@]VQ\+/A][8QX2TBOQ/,_^1EF'_837_P#3LS]*P/\
MN6#_ .O-+_TW$_E5_:'_ .2[_'+_ +*S\1?_ %*]5K]QRG3*\L\L+A__ $U$
M_+\?ICL;Y5ZO_IQGZ:?'7]ICQ7^S#^UYX5\1:0)M6\(:M\%OA98>//!XEV0Z
MYI42:N([VR#L$MO$5@KR26=P<!MTEM*?)N'Q\7EF34,YR"O1G:GB*>+Q+H5;
M?!+W='U<);27I):I'TV-S*IEN:4IQ7-1E0HJI#NDG^,=XM[>CDG^QO@WXF>!
MO'O@'3?B;X9\1:?=^"=2TB36TUR6>.UM;.QMHGDO_P"U&G91IL]B89X[N*X*
M-;O;2K)M*&OS[$8+$X3%3P5:C*.)A)0Y$KMMZ1Y;?$I73BU\2:MN?6T<30K4
M(XFG43HRCS<U[));\U_A<;-23V:=S^>[]N+]LC4OVB_$P^'WP_N+V'X/Z!JD
M<6G06T<Z7?Q$UZ*;R+?6[NU1?-DTM+A@NEV#)N<LMU*GG20QVOZOPSP]#**'
MUO%*+Q]2/O-VM0A:[@GMS6_B2_[=3LFY?!YUFT\?5^K8=M8:F]$MZDEIS-=E
M]F+VW?O:1^ _$6BZMX;U#6?#^O:==:1K>BSW>FZMI5]'Y5[IVH6NZ.YLKN')
M,-S#("CH>592IP00/JJ52G5ITZM*:G3J)2A*.THO9I]4^C/"<)TJOLYQ<)PE
M9Q>C33LTUT:/['_ HQX(\'#T\*^'A^6D6=?SWBO]YQ'_ %]J?^E,_6Z'\&C_
M ((?^DH_D4^-7_)6_B]_V4KQ_P#^I1JU?O>7:9?@/+#T/_343\HQ6F,Q/E7J
M?^EL_JT\/_$SX;^&O#7A31_$7Q!\$:!JUKX3\,O<:7K7BO0=*U&W2?1+*:!Y
MK*^OXIHEDA970L@#*P89!S7X;5P6,K5J]2CA*U6FZM2TH4IRCI-IV<8M:/1]
MC]0IXG#TJ5&%2O3ISC3A>,IQB_A36C:>QJGXT_!P G_A;/PS 7DD^._"P  Z
MY/\ :O&*C^S<P7_,!B%_W J__(E_7,'_ -!5'_P;#_Y(](AFAN(8KBWECGMY
MXXYH)X762&:&10\4L4B$K)&R,K*RD@@@@X-<;3BVFN5QT:>C372W2QT)II-.
MZ>S7X'X,?\%=?^2I?!_V\ :__P"I%#7ZAP#_ +EC_*M#_P!-GQ/%?\;#?X/_
M &Z1^8%KH'C30M!T/XH:=9ZQI>A+XHFTC0_&>FO+!'I_C#0HK+5/L<6H6S!]
M-U>&"ZM+J#>8VD7<T1?RI GVLJN&JU:F!G*$JOLU*=&5KNE.\;\KTE!M.,K7
MML[71\Q"%>E"&*A&48*?+&:V4XI2M=;-)IK9]5L[?T&_L,_MMV'QYTJW^''Q
M$N[33?C'HEEF.8^7:V?Q!TRSC'F:QI<0VI#KL,2[K_3XP!UNK9?(:2.S_*.)
MN&Y974>+PD7++ZCVW="3VC)]8-_!)_X9:V<OOLESB.-@J%=J.*@M]O:)=5TY
MDMTMU[RZJ/J/_!04X_9 ^,?_ &#O#8_\O3PY7%PIIG^7^4JG_IFH=&??\BK%
M>E/_ -.P/QJ_X)HC_C+GP?[>$_'O_IB85^A<9:9#7Z?O*/\ Z6CY+AO3,J?^
M&?\ Z1,_IAK\;/T4* "@ H 9))'!')+*Z10PHTDLDC!(XXXU+.[NQ 5%4$DD
M@  DTXQ<I*,4Y2DTDDKMMZ))+=MZ)"E*,(RE)J,(IMMNR22NVV]$DM6^A\._
M%;XCR>--3^P:;(Z>&M+F;[&HW)_:=RN4;4ID.,Q@;E@1A\J$N0&DPOZED&2Q
MRRA[6M%/&UTN?K[*.ZIQ??K-K=Z;+7\<XFS^6;XCV&'DXY?AI?NUJO:S6GM9
M+MTII[*\M'*R^<_'>HQ6'AG4T+[9[VW-G;H.6/G.D<C8[(L;-D^X'4U]CE=&
M57&T-/<I2YY/HN5-I>MTCX_%RY,-6?7EY5\]/R9\N7=U%96TMS+]R)>%Z%W/
M"1K_ +3-@?F>U?6XG$T\'0J8BH[1I+1=7+:,5YR>GX]#R<NR^OF>,H8'#KWZ
M[LWTA!:SJ2_NPC=^;LMV?,'C=+R;6IM6NI7G_M+:RNYR(6@C6(6B?W8HXE38
MO]W/<$U\%3J1J<[48TY2E*3C%6BG*3D[+M=G[JJ#PT*5'VDJD:5.$(SF[SDJ
M<5!<SZRTU.-K01QWB+7_ +,'TZPDQ<$%;JX0_P#'N#P8(F'_ "W(X9A]P<#Y
MB=N]"C[2TYK]VME_-;K_ (5_Y-Z;^3CL;:]"A+5:3FOQC%_F_DC8^!_B(>&O
MB7X=EDD\NSU6670+TDX41:JHBMV;V2_6T;GT-?GWC)D'^L'AYGU&G3Y\5E<(
M9GATEKSX)\]11_Q89UHZ=SRZ,N2I'HGI]^A^E9&..F./3&*_SS3T5MNAZ&WE
M8^OOV1O 7]K^)]2\=WT&ZP\,1MI^DEURDNN7\/\ I$R;@0QM--<CCD-J"$<I
M7ZIX79)]:S'$9U6A>CER]E0NM'B*D?>DNC]E2=O*55/='T/#^$]I7GBI+W*"
MY8?XY+5_]NQ_&2/T)U#4++2=/OM4U*YAL=.TRSN=0O[RX<1V]G964+W%U<SN
M>$AB@CD=F/14)[5^^0A*I.-.$7*<VHQBMVV[))=VW9'UTI1IQE*3Y8P3;;V2
M2NW\DC^2+]H_XQWGQW^,WCCXFW3RIINJ:BUEX8M)CC^S?"&D!K+P_;;.!%(]
ME']KF  S<7UPW5J_><GR^.5Y=AL%&W/3C>HUUJRUF_1-VC_=270_*LRQ<L;C
M*M=WM*5H+M%:15NCLE?^]=]3]<_V2/%WP8_8H^ _@W4OC1XC_P"$5\<?'T7'
MQ!6S_L;6=4U!?#=I';VGANVN(M)L+A[2UBTR[ANE,XC#3ZS=(NXQ/M^"S[#Y
MCQ'FF(AEU'V^&RJU"_/"$?:.[J-<TDF^9<KM?2$6]T?5Y75P>38&C+%U/9U<
M9^\^&4GR+X+\L6TFFY*^OO-=#NOCQ^U]^QA\<?A#XZ^&.H_%5(#XFT2>'2[R
M?P=XS(TS7[-DO] U,'_A'B5^S:O;6<C;<%D61,X<URY7P_Q%EF/PN-A@;^PF
MN:*K4?>@_=G'^)U@VEV=GT-L;FV3XW"5L-+$VYX^ZW3J:26L'\/225_*Z/Y]
M-(U;5/#NK:5KNC7CV&MZ#J=CJ^DZA;,RM::II5U%>6-W W!PEU!&XR 2!@CD
MBOU>I3A5ISI5(\U.K%PE%]8R5FGZIV/@X3E2J1G!\LJ<DXOJFG=-;V?;LS^N
M7X _%O2_CC\(? _Q-TPQ1MXBT>%M7LHF!_LKQ%9%K'Q!I;+N)3[-JUO=(F[!
M:+RI,8D&?P3-,!/+,?B<%._[F;Y&_M4W[T)?.+5^SNNA^K8'%1QF$HXB-ESQ
M]Y+I):27R:=NZL^I^6__  5_TZY\KX":N 39Q7'Q!TMVY*I=7$'A6\A4^A:&
MSN",]?*..AK[;P_G%/-*>TFJ$EZ)U4_N;1\QQ9"5L#.WNQ]JG\_9V.G_ ."0
MVLZ?)X&^,OAU7C75K+QCH&MS1D@2OIVJ:$UC:2A>IC2ZT>]4GH"V.XSCQ]3F
ML3E]6W[N5*<$^G-&=W^$D:\)SC[#%4[^_&<9->332_&+^\_8.OS\^M"@ H ^
M?/VL./V9_CM[?"WQE_Z9;JO6R+_D<Y7_ -A-'_TM'GYKIEN.\J-3_P!)9_.=
M^Q$/^,K_ ($^WC"3]/#NMU^N<2Z9%F?_ %Z_]OB? 9'IF>%\I']6E?AI^GA0
M!_(U^U5_R<?^T)[?%GQ^/IC7+T5^]9'IDV5?]@M#_P!(1^5YE_R,\9Y8BI_Z
M<D?U)_ WCX*?![V^%OP^_3PGI%?B>9_\C+,/^PFO_P"G9'Z5@=,%@_*A2_\
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M:I'XBTR $X#7^BP07H4?Q:'.1\TIS\UQSEGM*%#,Z4??P]J5:W_/N3_=R?\
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MOX2]O"/CS\/^)*!7J<9:9#7Z?O:/_I:.'AO_ )&5/RC/_P!(D?TOU^-GZ*%
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M\?W?/IKL?U6>#%:/P?X31E9'3PUH2LCJ4=&72[4%61@"K C!! ((Q7X?B/\
M>*__ %\G_P"E,_3*.E&ETM"/_I*/Y(_B[H6N2_%GXJ,N@ZW)')\2/'3(R:/J
M3QO&_BC5"K*RVI#(RD$$$@@Y%?O.7U:2P&!_>07+AZ.G-'I3CYGY5BZ53ZUB
M?=?\6HU_X&ST&W_:2_:YL[>"TM?BO\:8+:UABM[>"*XUI8X8($6*&*-?L7")
M&JJ!Z 5R/)\A;;>!PC;;;=H;O5]3I68YK%**Q%9**LESSZ:+J3?\-,_M@?\
M17/C9_X%:W_\A4O[%R#_ * ,)_X##_,?]I9M_P!!-;_P.?\ F?J-_P $R/BC
M\9OB)KOQ?A^*OC'QSXIM]*TKP=)HD?C"6^DCLYKJZU];U[ 7D$8#R)!;"39G
MB-,]J^)XSP.78*EE_P!1P]&@YRJ\_LE%724.6]NUW8^EX<Q6,Q%3%+%59S48
MT^53DW:[E>UV[;+L>)?\%:].U*]^*GPD:QTW4;U(_A_K2N]E87=VB,?$8(5V
MMX7"-@9P2#BO2X#G"&"QRE.,?W\;7:7_ "[\V<?%,)2KX;EC?EA_[=+^O+YG
MU5_P2FL[RR_9X\3Q7MG=V4K?%;Q"ZQ7EK/:2E#H/A<!UCN(T8H2"-P&,J1G(
M->'QQ*,LVH\LE)+#0V:?_+RKV/3X8BX8"JFN5^VEI_VY3/TWKXP^C.(^)'P\
M\+_%CP-XE^'?C.SEOO#/BK3GTW4X(+B2TN5021W%M=6ES%\T%Y;7D%O<POAE
M$ENA977*MTX/%UL!B:.*PTN6M0ES1;5UM9IKJI)M/R>C3U,<10IXFC4H55S4
MYJS771W37FFDUTNM4T?C?^S;^S%XU_9C_;P\+>'M=\W6/"6L>%/B'/X'\:Q6
MYBL]?L(M'5GL[M5REAXCLXV1;NSW8Y6>$O!*I'Z#G&=8?.>&*U6E^[KTJE!5
MJ-[N$N?1KO"7V9>J=FFCY/+LLJY;G-.$O>I24_9S_F7)+2W=?:733=--_N/7
MYJ?9!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #)(HYHW
MBEC26)U*O%(BO&ZGJKHP(9?8BFFXO1\K6UM :5K6T[&;;:%H=E*)[/1M*M)U
M)99K;3K2"4,1@D210JP..^:MU:LE:524EV<FU]S9"ITXOW81BUV27Y(U:S+"
M@ H S;_1M'U4*-4TK3=2"J547]C:W@52<E5%Q$^%SS@5<*E2G_#J2A_ADU^3
M1,H0E\4(RMW2?YDMCING:7%]GTRPLM.@SGR+&U@M(LC@'R[>-%R/I2E.<W><
MG)KK)MO\0C&,%:,5%=DDOR+M24% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M 1/##(\,DD4;R6[M);N\:L\#O&\+O"S F)VBDD0E2"5=E/#$%IM)I.R>Z_'7
MYJXK+33X=O+IIV):0PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
("@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d255444d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abos-20211115.xsd" xlink:type="simple"/>
    <context id="duration_2021-11-15_to_2021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576885</identifier>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-11-15_to_2021-11-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-11-15_to_2021-11-15"
      id="Hidden_dei_EntityCentralIndexKey">0001576885</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-11-15_to_2021-11-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-11-15_to_2021-11-15">2021-11-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-11-15_to_2021-11-15">Acumen Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-11-15_to_2021-11-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-11-15_to_2021-11-15">001-40551</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-11-15_to_2021-11-15">36-4108129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-11-15_to_2021-11-15">427 Park St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-11-15_to_2021-11-15">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-11-15_to_2021-11-15">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-11-15_to_2021-11-15">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-11-15_to_2021-11-15">(434)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-11-15_to_2021-11-15">297-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-11-15_to_2021-11-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-11-15_to_2021-11-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-11-15_to_2021-11-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-11-15_to_2021-11-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-11-15_to_2021-11-15">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-11-15_to_2021-11-15">ABOS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-11-15_to_2021-11-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-11-15_to_2021-11-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2021-11-15_to_2021-11-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140203382268952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 15,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acumen Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4108129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">427 Park St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABOS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%'?KF1$^/ )6V+Z^@#(,:KNGY?+$_.%Z362L<GZ&V_1_R![RO "R)L &V4;
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( (%!;U.KA9 5[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( (%!;U.97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ @4%O
M4R/FT )/!   V1   !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( (%!;U.?H!OPL0(  .(,   -
M      "  9$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ @4%O4Y>*NQS
M    $P(   L              ( !;0\  %]R96QS+RYR96QS4$L! A0#%
M  @ @4%O4QPX9>H_ 0  / (   \              ( !5A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( (%!;U,D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M (%!;U-ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d255444d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d255444d8k.htm">d255444d8k.htm</File>
    <File>abos-20211115.xsd</File>
    <File>abos-20211115_lab.xml</File>
    <File>abos-20211115_pre.xml</File>
    <File>d255444dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d255444d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d255444d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abos-20211115_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abos-20211115_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abos-20211115.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "abos",
   "nsuri": "http://www.acumenpharm.com/20211115",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d255444d8k.htm",
      "contextRef": "duration_2021-11-15_to_2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d255444d8k.htm",
      "contextRef": "duration_2021-11-15_to_2021-11-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acumenpharm.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-329003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-329003-xbrl.zip
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MW+YM<";+"GWM059XMA3_AZ66Z^ @+P]88-[%W>XQ7^;-4BSY&U!+ P04
M" "!06]30EI%M1$/  "480  #@   &0R-34T-#1D.&LN:'1M[5SK<]JX%O^^
M,_L_:.CM#IF) 1OR@#QV4D*[W+8D ^S=G?W2$;8(NC6V*\D![E]_SY$?F%>
M!))M-YDVP>AU='0>OW,D^?S7\= E]TQ([GL7.;-0RA'FV;[#O;N+7*CZQFF.
M_'KY\T_G P45H;(G:P[C%[F!4D&M6!SWA%N0S"[<^?=%*"A:):MDE$RC;.;B
MZJ$TU"1@,FW3I[)7\,5=,2E9TLCS/2\<IDU&HU%!#X7-'"6*V*X(E0RHQ02W
MDW9CEWM?9YJ-RKJ16:U6B[HTJ;I0,QW *I7*12SN4<F2ZK3GRYGJU(:AO6!
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M66V]CE=0JWD"5@=8AUF_[8S9#1Y,C6XW1C0G5QP/R4-7VT@>C0,>NK! RM8
MEX5B_;G&%2RDK>$J6LX4-N@_NFOS[""]!9HQ:2+F*/*P%TK0'BG) $9T<52I
M3222]RW4]]=(9$H[##SF=)[E4C3/ KD"&Q5,4M<:Z(-1 BPS!6N\PWDVJ/#
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MG%%4]BY)H,=%FZ+B\V+T"GC]@OC+_P-02P,$%     @ @4%O4\$*3DYK$@
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MR\? % !>T5+7Q6=I2)I\;B:T#/I%_"^5,QX2S83&4+43#O@-. !C@MX),-Y
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ML-VU V\'W=_A)OVQQ_\#4$L! A0#%     @ @4%O4Q#RAVA, P  A L  !$
M             ( !     &%B;W,M,C R,3$Q,34N>'-D4$L! A0#%     @
M@4%O4]V@T3^0!@  .D<  !4              ( !>P,  &%B;W,M,C R,3$Q
M,35?;&%B+GAM;%!+ 0(4 Q0    ( (%!;U,C*+4,T@0  -,L   5
M      "  3X*  !A8F]S+3(P,C$Q,3$U7W!R92YX;6Q02P$"% ,4    " "!
M06]30EI%M1$/  "480  #@              @ %##P  9#(U-30T-&0X:RYH
M=&U02P$"% ,4    " "!06]3P0I.3FL2  #S40  $0              @ &
J'@  9#(U-30T-&1E>#DY,2YH=&U02P4&      4 !0!  0  &C$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
